News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,717 Results
Type
Article (39821)
Company Profile (255)
Press Release (660641)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204388)
Career Advice (2012)
Deals (35448)
Drug Delivery (95)
Drug Development (81142)
Employer Resources (172)
FDA (16199)
Job Trends (14880)
News (345551)
Policy (32569)
Tag
Academia (2555)
Accelerated approval (5)
Adcomms (21)
Allergies (86)
Alliances (49515)
ALS (96)
Alzheimer's disease (1385)
Antibody-drug conjugate (ADC) (136)
Approvals (16193)
Artificial intelligence (266)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11645)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (183)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2329)
Cardiovascular disease (179)
Career advice (1679)
Career pathing (30)
CAR-T (157)
Cell therapy (440)
Cervical cancer (20)
Clinical research (66161)
Collaboration (861)
Company closure (2)
Compensation (569)
Complete response letters (20)
COVID-19 (2596)
CRISPR (41)
C-suite (251)
Cystic fibrosis (102)
Data (2338)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6385)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (97)
Earnings (87101)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112821)
Executive appointments (746)
FDA (17580)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (779)
Gene editing (109)
Generative AI (20)
Gene therapy (318)
GLP-1 (719)
Government (4433)
Grass and pollen (4)
Guidances (162)
Healthcare (18836)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (127)
Indications (29)
Infectious disease (2741)
Inflammatory bowel disease (144)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (313)
IPO (16541)
IRA (40)
Job creations (3642)
Job search strategy (1424)
Kidney cancer (10)
Labor market (43)
Layoffs (476)
Leadership (17)
Legal (7912)
Liver cancer (76)
Lung cancer (325)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (77)
Medical device (13387)
Medtech (13392)
Mergers & acquisitions (19483)
Metabolic disorders (708)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (95)
Neuropsychiatric disorders (27)
Neuroscience (1946)
NextGen: Class of 2025 (6523)
Non-profit (4481)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (82)
Pain (92)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57427)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20627)
Phase II (29145)
Phase III (21690)
Pipeline (1385)
Policy (148)
Postmarket research (2564)
Preclinical (8776)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (387)
Real estate (5920)
Recruiting (65)
Regulatory (22353)
Reports (48)
Research institute (2322)
Resumes & cover letters (350)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (133)
Series B (92)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3587)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (137)
Last 7 days (993)
Last 30 days (3250)
Last 365 days (32486)
2025 (12004)
2024 (35253)
2023 (40104)
2022 (51230)
2021 (55762)
2020 (54123)
2019 (46565)
2018 (35041)
2017 (32144)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37962)
Australia (6217)
California (6444)
Canada (2075)
China (540)
Colorado (275)
Connecticut (281)
Delaware (160)
Europe (81553)
Florida (958)
Georgia (216)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (927)
Massachusetts (4786)
Michigan (226)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1812)
North Carolina (995)
North Dakota (8)
Northern California (2845)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1444)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2416)
Tennessee (106)
Texas (958)
United States (24136)
Utah (188)
Virginia (152)
Washington D.C. (64)
Washington State (567)
West Virginia (3)
Wisconsin (57)
700,717 Results for "atara biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
May 5, 2025
·
6 min read
Layoffs
Atara Halves Workforce Again, Pauses 2 CAR T Programs
Less than two months after two FDA-related setbacks, Atara Biotherapeutics is again cutting its workforce in half. This time, it’s also hitting pause on two CAR T programs, including one affected by an FDA clinical hold in January.
March 4, 2025
·
2 min read
·
Angela Gabriel
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Atara to Cut Half Its Workforce Following FDA-Related Setbacks
Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected Ebvallo, a T cell therapy approved in Europe for a transplant-related blood cancer, and placed a clinical hold on the company’s active drug applications.
January 28, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 7, 2025
February 9, 2025
·
1 min read
Press Releases
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
March 7, 2025
·
13 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.
June 7, 2024
·
2 min read
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market just yet, forcing the company to “significantly reduce expenses.”
January 16, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
January 16, 2025
·
9 min read
Deals
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
Atara Biotherapeutics, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 (the “Reverse Stock Split”).
June 17, 2024
·
5 min read
1 of 70,072
Next
